| Name | Title | Contact Details |
|---|---|---|
Ivor D`Souza |
Acting Director of Center for Information Technology | Profile |
Andrea Ramirez |
Chief Data Officer | Profile |
Connie Latzko |
Chief Information Officer, National Institute on Deafness and Other Communication Disorders (NIDCD) | Profile |
David Olson |
Chief Information Security Officer | Profile |
Ramesh Varanasi |
Deputy Chief Information Security Officer | Profile |
MacPractice is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lead Health is a national healthcare staffing firm based in California that provides opportunities in travel nursing, per diem nursing, and allied healthcare.
TreyMed is a Sussex, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced womens health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.